Sometimes a single error in DNA can halt the production of a vital protein. The cell begins reading a gene, reaches a randomly occurring stop signal, and prematurely stops assembling the molecule. As a result, the protein is truncated and often unable to perform its function at all.
This is exactly how nonsense mutations act—the cause of many hereditary diseases. Now researchers have proposed an unusual way to bypass such an error: not by fixing the gene itself, but by altering how the cell reads its instructions.
A team of scientists has developed a modified transfer RNA—tRNA. Normally, these small molecules act as translators between the genetic code and proteins: each tRNA recognizes a specific codon in mRNA and brings the appropriate amino acid to the growing protein chain. The researchers modified tRNA so that it can recognize a premature stop codon and, instead of halting synthesis, continue assembling the protein.
In other words, the cell receives a false "stop" command, but the modified tRNA helps it understand: here the period is placed by mistake, so it should read on.
The scientists also introduced a chemical modification, N¹-methyladenosine, into the molecule. This made the tRNA more stable, increased its efficiency, and reduced unwanted activation of the innate immune system.
But there was another problem: the tRNA needed to be delivered inside cells. To this end, the researchers created specialized lipid nanoparticles adapted specifically for tRNA transport.
The technology was tested on cystic fibrosis—a disease in which some mutations in the CFTR gene create premature stop codons. As a result, the cell cannot properly produce the CFTR protein, which regulates ion transport across the membrane of epithelial cells.
In airway cells, the modified tRNA helped restore synthesis of full-length CFTR. In some models, the functional effect persisted for more than forty days.
Very interesting results were obtained on organoids grown from a patient's cells with a CFTR variant that barely responded to existing drugs. Individually, the effect was weak: neither the tRNA nor the drug Trikafta provided full functional restoration. But together they worked significantly better.
First, the tRNA allowed the cell to finish assembling the protein despite the premature stop codon. Then Trikafta helped this protein fold correctly, reach the membrane, and perform its function. This gave rise to a potential combination strategy: first restore the protein itself, then help it work.
Nonsense mutations are not limited to cystic fibrosis. They are associated with about a tenth of hereditary genetic diseases and are found in a wide range of pathologies—from certain muscular dystrophies to rare neurological syndromes.
Moreover, premature stop signals are based on just three stop codons of the genetic code. Therefore, theoretically, the same strategy could be used for different diseases if they are caused by a similar type of error.
This does not mean that one tRNA will become a universal cure for thousands of diseases. Everything will depend on the specific gene, the location of the mutation, the required amino acid, and the tissues into which the molecule needs to be delivered. But the principle itself indeed opens the possibility of creating platform drugs instead of a separate therapy for each rare mutation.
The study remains preclinical: the technology has been tested on cells, organoids, and animal models. Scientists will need to ensure that the modified tRNA does not accidentally skip normal stop codons that should terminate ordinary proteins. They also need to improve delivery systems and thoroughly study possible immune and inflammatory responses.
Modern genetic medicine increasingly attempts to repair damaged DNA. Here, a different path is chosen: the gene remains unchanged, and intervention occurs at the stage of reading its instructions.
